

### Supplementary Material

#### **The influence of home versus clinic anal human papillomavirus sampling on high-resolution anoscopy uptake in the Prevent Anal Cancer Self-Swab Study**

*Jenna Nitkowski<sup>A,\*</sup>, Timothy J. Ridolfi<sup>B</sup>, Sarah J. Lundeen<sup>B</sup>, Anna R. Giuliano<sup>C</sup>, Elizabeth Y. Chiao<sup>D</sup>, Maria E. Fernandez<sup>E</sup>, Vanessa Schick<sup>F</sup>, Jennifer S. Smith<sup>G</sup>, Bridgett Brzezinski<sup>A</sup>, and Alan G. Nyitray<sup>A,H</sup>*

<sup>A</sup>Center for AIDS Intervention Research (CAIR), Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

<sup>B</sup>Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.

<sup>C</sup>Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

<sup>D</sup>MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.

<sup>E</sup>Department of Health Promotion and Behavioral Sciences, The University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.

<sup>F</sup>Department of Management, Policy and Community Health, The University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA.

<sup>G</sup>Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

<sup>H</sup>Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.

\*Correspondence to: Jenna Nitkowski Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, 2153 N. Dr. Martin Luther King, Jr. Dr., Milwaukee, WI 53212, USA Email: [jnitkowski@mcw.edu](mailto:jnitkowski@mcw.edu)

# HIGH-RESOLUTION ANOSCOPY ATTENDANCE

*Supplemental Table S1.* Characteristics of participants who engaged in screening, stratified by study arm and HRA attendance in the Prevent Anal Cancer Self-Swab Study, Milwaukee, Wisconsin, 2020-2023 (n=196).

	HOME (n=107)			CLINIC (n=89)		
	Attended HRA n=62	Did not attend HRA n=45	p-value	Attended HRA n=61	Did not attend HRA n=28	p-value
<b>Age, years</b> Mean, Range	47.5, 27-78	44.2, 25-74	0.19 <sup>a</sup>	47.0, 25-77	46.5, 25-69	0.86 <sup>a</sup>
<b>Age, years</b>			0.22 <sup>b</sup>			0.91 <sup>b</sup>
25-34	17 (54.8)	14 (45.2)		18 (66.7)	9 (33.3)	
35-44	9 (45.0)	11 (55.0)		10 (71.4)	4 (28.6)	
45-54	12 (60.0)	8 (40.0)		13 (76.5)	4 (23.5)	
55+	24 (66.7)	12 (33.0)		20 (64.5)	11 (35.5)	
<b>Gender identity</b>			0.57 <sup>c</sup>			0.18 <sup>c</sup>
Man	61 (58.7)	43 (41.3)		56 (66.7)	28 (33.3)	
Trans, non-binary, or other	1 (33.3)	2 (66.7)		5 (100.0)	0 (0.0)	
<b>Sexual orientation</b>			0.79 <sup>c</sup>			0.65 <sup>c</sup>
Gay	54 (59.3)	37 (40.7)		54 (69.2)	24 (30.8)	
Bisexual	7 (50.0)	7 (50.0)		3 (50.0)	3 (50.0)	
Queer or lesbian	1 (50.0)	1 (50.0)		3 (75.0)	1 (25.0)	
<b>Race/ethnicity</b>			0.19 <sup>c</sup>			0.14 <sup>c</sup>
White, non-Hispanic	41 (59.4)	28 (40.6)		49 (73.1)	18 (26.9)	
Black, non-Hispanic	11 (44.0)	14 (56.0)		5 (41.7)	7 (58.3)	
Hispanic or Latino/x	9 (75.0)	3 (25.0)		6 (66.7)	3 (33.3)	
Other, non-Hispanic	0 (0.0)	0 (0.0)		1 (100.0)	0 (0.0)	
<b>Education, years</b> <sup>d</sup>			0.27 <sup>b</sup>			0.06 <sup>b</sup>
≤ 12	2 (28.6)	5 (71.4)		7 (63.6)	4 (36.4)	
13-15	17 (54.8)	14 (45.2)		11 (52.4)	10 (47.6)	
16	14 (70.0)	6 (30.0)		12 (66.7)	6 (33.3)	
> 16	29 (59.2)	20 (40.8)		31 (79.5)	8 (20.5)	
<b>HIV status</b>			0.90			0.02
Negative	42 (57.5)	31 (42.5)		55 (73.3)	20 (26.7)	
Positive	20 (58.8)	14 (41.2)		6 (42.9)	8 (57.1)	
<b>Ever had HRA</b>			0.07 <sup>c</sup>			0.99 <sup>c</sup>
Yes	10 (83.3)	2 (16.7)		2 (66.7)	1 (33.3)	
No or don't know	52 (54.7)	43 (45.3)		58 (68.2)	27 (31.8)	
<b>Ever had anal cytology</b>			0.06			0.77 <sup>c</sup>
Yes	23 (71.9)	9 (28.1)		11 (73.3)	4 (26.7)	
No or don't know	39 (52.0)	36 (48.0)		50 (67.6)	24 (32.4)	
<b>Preferred anal sex position</b>			0.09 <sup>c</sup>			0.32 <sup>c</sup>
Insertive	15 (65.2)	8 (34.8)		15 (83.3)	3 (16.7)	
Receptive	23 (69.7)	10 (30.3)		15 (71.4)	6 (28.6)	
Versatile	23 (46.9)	26 (53.1)		27 (60.0)	18 (40.0)	
Never engaged in anal sex	0 (0.0)	1 (100.0)		3 (75.0)	1 (25.0)	
<b>Afraid to have anal cancer screening for fear of a bad result</b>			0.32 <sup>c</sup>			0.15
Strongly agree or agree	4 (40.0)	6 (60.0)		6 (50.0)	6 (50.0)	
Strongly disagree or disagree	58 (59.8)	39 (40.2)		54 (71.1)	22 (28.9)	
<b>Ever been diagnosed with anal warts</b>			0.11			0.29
Yes	20 (71.4)	8 (28.6)		13 (59.1)	9 (40.9)	
No	42 (53.8)	36 (46.2)		47 (71.2)	19 (28.8)	
<b>Abnormality detected in baseline DARE</b>			0.49			0.52
Yes	22 (73.3)	8 (26.7)		26 (65.0)	14 (35.0)	
No	33 (66.0)	17 (34.0)		35 (71.4)	14 (28.6)	
Did not attend baseline DARE	7	20		--	--	
<b>Abnormality referral</b>			0.99 <sup>c</sup>			0.47 <sup>c</sup>
Yes	7 (77.8)	2 (22.2)		6 (54.5)	5 (45.5)	
No	15 (71.4)	6 (28.6)		20 (69.0)	9 (31.0)	

Abbreviations: HRA, high-resolution anoscopy; DARE, digital anal rectal examination. Missing: sexual orientation n=1; race/ethnicity n=1, ever had HRA n=1; preferred anal sex position n=2; afraid to have anal cancer screening for fear of a bad result n=1; ever been diagnosed with anal warts n=2. Pearson chi-square tests were conducted unless otherwise noted.

<sup>a</sup> t-test.

<sup>b</sup> Cochran-Armitage test for trend.

<sup>c</sup> Fisher's exact test.